Next-Generation Pharma Company

Focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet need

Pipeline

INHBE (Activin E)

Phase 1

Indication

Obesity

Est. Ph I Initiation

H2 2025

Modality

siRNA

TL1A HLE

Phase I
TL1A-VIAL-HLE has started a phase 1 trial and remains on track to have an interim data readout in H2 2025

Indication

Inflammatory bowel disease (IBD)

Next Data Catalyst

Interim data readout in H2 2025

Modality

Monoclonal antibody
TL1A antibody diagram.

IL-13 x TSLP

Preclinical

Indication

Atopic Dermatitis, Asthma, Chronic Sinusitis

Est. Ph I Initiation

H2 2025

Modality

Half-life extended bi-specific antibody

TMPRSS6​

Preclinical

Indication

Polycythemia Vera

Est. Ph I Initiation

Q1 2026

Modality

siRNA

Myostatin (GDF8)

Preclinical

Indication

Obesity

Est. Ph I Initiation

H2 2025

Modality

Half-life extended monoclonal antibody

α4β7 x IL-23

Preclinical

Indication

Inflammatory bowel disease (IBD)

Est. Ph I Initiation

H2 2025

Modality

Bi-specific antibody
Get in touch

Our model is powered by a computational discovery engine and highly automated clinical trials

Clip art of grey boxes with purple symbols and fake code
Clip art of grey boxes with purple symbols and fake code
molecule-icon

Computationally Enabled Discovery.

Computationally enabled discovery platform delivers programs with best-in-class, differentiated profiles at-scale.

Flowchart
Flow chart moving left to right showing the flow of records

Automated Clinical Trials.

Leveraging technology to automate clinical trials, enhancing precision and efficiency in drug development.

Recent Updates

Stay updated on recent news and upcoming events.